PMV Pharmaceuticals, Inc. (PMVP)

NMS – Цена в реальном времени. Валюта: USD

1.19

+0.04 (3.48%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

1.19

0.00 (0.00%)

После закрытия: Jun 26, 2026, 4:10 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

PMV Pharmaceuticals, Inc. (PMVP)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

PMV Pharmaceuticals, Inc. (PMVP)

PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PMV Pharmaceuticals (PMVP) Q2 Loss Jumps

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

Видео

No Data

Пресс-релизы

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

Search stocks

PMV Pharmaceuticals, Inc. (PMVP)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

PMV Pharmaceuticals, Inc. (PMVP)

PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PMV Pharmaceuticals (PMVP) Q2 Loss Jumps

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

Видео

No Data

Пресс-релизы

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights